Cell division

WINNERS OF THE 2023 BREAKTHROUGH PRIZES IN LIFE SCIENCES, MATHEMATICS AND FUNDAMENTAL PHYSICS ANNOUNCED

Retrieved on: 
Thursday, September 22, 2022
Universe, Breakthrough Prize in Life Sciences, Entrepreneurship, Algorithm, Human, Neurodegeneration, Narcolepsy, Creativity, Wakefulness, Achievement, Pioneer Field (Tusculum), Foundation, Deep learning, Membrane, BB84, Doctor of Philosophy, Organic acid, Sleep, ALS, Research, Animal, DeepMind, Mutation, Communication, Disease, Breakthrough Prize in Fundamental Physics, 3D, Life, Breakthrough Prize in Mathematics, Science, Behavior, DNA, AlphaFold, CZI, Woman, Jumper, Breakthrough, Computer, Synthetic biology, Breakthrough Prize, Cell nucleus, Biology, Logic, Method, Immune system, Dog, Yanagisawa, Engineering, Protein, Drug design, Program, Cell division, List of life sciences, Cell, Interaction, Organelle, RNA, Neuron, AI, Microscope, Pharmaceutical industry, Wool, Phosphorus, Mathematics, Physics

The Breakthrough Prize in Mathematics goes to Daniel A. Spielman, for multiple discoveries in theoretical computer science and mathematics.

Key Points: 
  • The Breakthrough Prize in Mathematics goes to Daniel A. Spielman, for multiple discoveries in theoretical computer science and mathematics.
  • The Breakthrough Prize in Fundamental Physics is shared by Charles H. Bennett, Gilles Brassard,David Deutsch and Peter Shorfor their foundational work in quantum information.
  • And important contributions from early-career scientists are also recognized, with six New Horizons Prizes in Physics and Mathematics and three Maryam Mirzakhani New Frontiers Prizes awarded for women mathematicians who have recently completed their doctorates.
  • Each of the five main prizes is $3 million, and the addition of the early-career awards brings this year's total prizes to $15.75 million.

WINNERS OF THE 2023 BREAKTHROUGH PRIZES IN LIFE SCIENCES, MATHEMATICS AND FUNDAMENTAL PHYSICS ANNOUNCED

Retrieved on: 
Thursday, September 22, 2022
Universe, Breakthrough Prize in Life Sciences, Entrepreneurship, Algorithm, Human, Neurodegeneration, Narcolepsy, Creativity, Wakefulness, Achievement, Pioneer Field (Tusculum), Foundation, Deep learning, Membrane, BB84, Doctor of Philosophy, Organic acid, Sleep, ALS, Research, Animal, DeepMind, Mutation, Communication, Disease, Breakthrough Prize in Fundamental Physics, 3D, Life, Breakthrough Prize in Mathematics, Science, Behavior, DNA, AlphaFold, CZI, Woman, Jumper, Breakthrough, Computer, Synthetic biology, Breakthrough Prize, Cell nucleus, Biology, Logic, Method, Immune system, Dog, Yanagisawa, Engineering, Protein, Drug design, Program, Cell division, List of life sciences, Cell, Interaction, Organelle, RNA, Neuron, AI, Microscope, Pharmaceutical industry, Wool, Phosphorus, Mathematics, Physics

The Breakthrough Prize in Mathematics goes to Daniel A. Spielman, for multiple discoveries in theoretical computer science and mathematics.

Key Points: 
  • The Breakthrough Prize in Mathematics goes to Daniel A. Spielman, for multiple discoveries in theoretical computer science and mathematics.
  • The Breakthrough Prize in Fundamental Physics is shared by Charles H. Bennett, Gilles Brassard,David Deutsch and Peter Shorfor their foundational work in quantum information.
  • And important contributions from early-career scientists are also recognized, with six New Horizons Prizes in Physics and Mathematics and three Maryam Mirzakhani New Frontiers Prizes awarded for women mathematicians who have recently completed their doctorates.
  • Each of the five main prizes is $3 million, and the addition of the early-career awards brings this year's total prizes to $15.75 million.

Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance

Retrieved on: 
Tuesday, September 20, 2022
LR, Chromosome, Infection, CHF, PLK1, Neoplasm, Intention, Mycosis, Mitosis, Achievement, USD, Patient, Cell division, Cancer, Isavuconazonium, SIX Swiss Exchange, CEO, SAC, CA, Renal cell carcinoma, Chromosome segregation, Research, TTK, Communication, Online gambling, Pharmaceutical industry, Vaccine, SillaJen, MD, Basel

Under the asset purchase agreement Basilea is selling its intellectual property rights generated under the license and collaboration agreement with NTRC.

Key Points: 
  • Under the asset purchase agreement Basilea is selling its intellectual property rights generated under the license and collaboration agreement with NTRC.
  • In addition, Basilea is sub-licensing its rights and obligations under the license and collaboration agreement with NTRC to SillaJen.
  • Adesh Kaul, Chief Financial Officer of Basilea, said: We are pleased to have found in SillaJen an experienced oncology partner for the further development of BAL0891.
  • Jaegyeong Kim, MD, CEO at SillaJen, Inc. stated: We are excited to acquire the rights to BAL0891.

Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference

Retrieved on: 
Friday, September 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Partnership, Cancer, Experimental biology, Bristol Myers Squibb, Cell division, Aneuploidy, Microsoft, Therapy, Chromosome, Dana–Farber Cancer Institute, FASEB, CIN, Cell, Method, KIF18A, Conference, Prevalence, The FASEB Journal, Federation, Patient, Pharmaceutical industry, Volastra

Leveraging its proprietary CINtech platform, Volastra discovered that CIN-high cancer cells are more dependent on chromosome alignment machinery like KIF18A and are thus more vulnerable to KIF18A inhibition than normal cells.

Key Points: 
  • Leveraging its proprietary CINtech platform, Volastra discovered that CIN-high cancer cells are more dependent on chromosome alignment machinery like KIF18A and are thus more vulnerable to KIF18A inhibition than normal cells.
  • These findings set our KIF18A inhibitor apart from traditional chemotherapies, which can have a detrimental impact on healthy cells.
  • We anticipate initiating a Phase 1 study for this potential best-in-class KIF18A inhibitor in the second half of 2023.
  • These new data from Volastras KIF18A inhibitor further support the promise of developing new and better cancer therapies through a deep understanding of this vulnerability.

PHBI Pharmagreen Develops a Proprietary Nutraceutical Formulation and Prepares for Product Launch

Retrieved on: 
Thursday, September 8, 2022
Emerald, Lipopolysaccharide, Plant, Technology, OTCQB, CEO, Research, Cell division, Gene, Friends, Genetics, Protein, Nutrient, Heart, USD, OTC Markets Group, DNA, Science, Diet, GLOBE, Long Valley Farm, Nutritional genomics, Company, Family, Cannabis, CAGR, News, Fungus, Knowledge, Risk, Acquisition, Amazon, Health, Forward-looking statement, Aquaculture, Medicinal plants, Shopify

The Pharmagreen team is very excited to be launching this nutraceutical product utilizing a combination of fifteen ingredients from medicinal plants and mushrooms.

Key Points: 
  • The Pharmagreen team is very excited to be launching this nutraceutical product utilizing a combination of fifteen ingredients from medicinal plants and mushrooms.
  • Pharmagreens proprietary blend is unique to the market, a nutrigenomic supplement for the utmost mind and body experience.
  • Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level.
  • Pharmagreen is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product.

DGAP-News: Defence Therapeutics Inc.: BREAKTHROUGH DISCOVERY: ACCUTOXTM EFFECTIVELY KILLS CANCER CELLS BY DIRECTLY ELICITING DNA DAMAGE

Retrieved on: 
Tuesday, August 2, 2022
DNA, Neoplasm, Catastrophic illness, Cell division, Cell death, Protein, ADC, CEO, Forward-looking statement, Survival rate, Therapy, DNA-directed RNA interference, Control, News, Cancer, Cell proliferation, Chemistry (relationship), GLP, Cell, Technology, Antibody-drug conjugate, Company, DNA replication, Infection, CSE, Mouse, Engineering, DGAP, Defense, Vaccine, Security (finance), BC

Although it is difficult to reactivate these specific pathways to elicit cancer cell death, AccuTOXTM can address this.

Key Points: 
  • Although it is difficult to reactivate these specific pathways to elicit cancer cell death, AccuTOXTM can address this.
  • Defence previously reported (see press release of June 22, 2021) the discovery of an AccumTM variant, AccuTOXTM, capable of controlling cancer growth when injected directly in tumors.
  • "Defences breakthrough discovery with its AccuTOXTM formulation as a novel potent small molecule capable of killing cancer cells is a significant advancement and development for oncology cancer treatment applications with AccumTM.
  • Defence is currently conducting GLP studies on AccuTOXTM prior to initiate a Phase I trial in North America.

Team Led by Boundless Bio Scientific Founders Receives $25M Award to Better Understand Extrachromosomal DNA (ecDNA) Through Cancer Grand Challenges

Retrieved on: 
Thursday, June 16, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, EGFR, Cancer, Department, Therapy, University of California, San Diego, Oncogene, Chemical biology, CRUK, Boundless, National, Biology, Scripps Research, Research, Survival, Computer science and engineering, Bio, Recurrence, Growth, DNA, Jackson Laboratory, Computational biology, University, Professor, News, Stanford University, Rolling circle replication, Associate, Radiation, Cancer Research UK, NCI, Patient, Chromosome, Florine, Computer science, Genomics, National Cancer Institute, Glioblastoma, Cell division, Immunotherapy, Dietary supplement, Management, Pharmaceutical industry, Sales, Genetics

has been awarded $25 million in funding by the National Cancer Institute (NCI*) and Cancer Research UK (CRUK) through Cancer Grand Challenges to deepen the understanding of the role of ecDNA in cancer pathogenesis.

Key Points: 
  • has been awarded $25 million in funding by the National Cancer Institute (NCI*) and Cancer Research UK (CRUK) through Cancer Grand Challenges to deepen the understanding of the role of ecDNA in cancer pathogenesis.
  • We at Boundless continue to be inspired by Dr. Mischel and the eDyNAmiC scientific teams commitment to advancing the scientific understanding of ecDNA.
  • Extrachromosomal DNA (ecDNA) are circular units of nuclear DNA that are physically distinct from chromosomes and are found within cancer cells.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.

mTOR (Mammalian Target of Rapamycin) Inhibitors Market Analysis Report 2022 by Drug Type, Indication, Route of Administration - Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 14, 2022
Health, Pharmaceutical, Kidney, Cell division, Sirolimus, US, Marketing, Blood, Market share, MTOR inhibitors, Route of administration, Food, Towa Pharmaceutical Ractab Dome, Breast cancer, Cancer, Office of Inspector General, U.S. Department of Health and Human Services, U.S. Department of Defense Strategy for Operating in Cyberspace, Pancreatic cancer, MTOR, Wilms' tumor, Everolimus, Growth, Human services, Lists of diseases, Region, Prevalence, Industry, Renal cell carcinoma, Regulation of tobacco by the U.S. Food and Drug Administration, Neoplasm, Administration, CAGR, Lymphangioleiomyomatosis, Pharmaceutical industry, Generic drug, Fine chemical, Temsirolimus

The "mTOR Inhibitors Market, by Drug Type, By Indication, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "mTOR Inhibitors Market, by Drug Type, By Indication, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Increasing product approvals from regulatory bodies is expected to drive the growth of global mTOR Inhibitors market during the forecast period.
  • Increasing number of prevalence of renal cell carcinoma is expected to drive the growth of global mTOR inhibitors market.
  • Mammalian target of rapamycin (mTOR) has common and serious class side effects of mTOR inhibitors include non-infectious pneumonitis, metabolic disorders and mucosal toxicity.

Global HPAPIs and Cytotoxic Drugs Manufacturing Market Analysis Report 2022-2030: Drug Origin, Manufacturing Location, Drug Type, Type of Pharmacological Molecule, Application - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 14, 2022
Health, Pharmaceutical, Molecule, Cell division, Radiation, US, Type, 2009 Davis Cup, Marketing, Control, Teva, Metastasis, Growth, Antibody-drug conjugate, Swissmedic, Region, CGMP, Industry, Cytotoxicity, Application, Neoplasm, CAGR, API, Fine chemical

The "HPAPIs and Cytotoxic Drugs Manufacturing Market, by Drug Origin, by Manufacturing Location, by Drug Type, by Type of Pharmacological Molecule, by Application, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HPAPIs and Cytotoxic Drugs Manufacturing Market, by Drug Origin, by Manufacturing Location, by Drug Type, by Type of Pharmacological Molecule, by Application, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Highly potent active pharmaceutical ingredients (HPAPIs) have an increasingly significant share of the pharmaceutical drug pipeline including anti-cancer treatments.
  • Manufacturing highly potent APIs in large volumes requires extensive project experience with HPAPIs and a strong track record for audits and supply security.
  • Key players are focusing on receiving authorizations for their manufacturing facilities, from the regulatory authorities, and this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period.

New Study Identifies Potential Therapeutic Target for Gastric Cancer

Retrieved on: 
Monday, June 6, 2022
Cell division, Drug resistance, Immunohistochemistry, Experimental Biology and Medicine, Experimental Biology and Medicine (Society for Experimental Biology and Medicine journal), Neoplasm, Nantong University, Publishing, Drug tolerance, Society, Stomach cancer, Hereditary diffuse gastric cancer, Therapy, Stomach, BVES, Cell adhesion, GLOBE, Patient, Experimental biology, Mortality, Movement, PDX, Institute, Cancer, Medical device, Pharmaceutical industry, MSI1, Medicine

Drug resistance accounts for most of the mortality of gastric cancer.

Key Points: 
  • Drug resistance accounts for most of the mortality of gastric cancer.
  • Musashi-1 (MSI1) is an RNA-binding protein that is considered a gastric and intestinal stem cell marker and may act as a biomarker and therapeutic target for gastric cancer.
  • Therefore, the authors posited that a clear understanding of the role of MSI1 in gastric cancers may lead to more effective therapeutics for treating gastric cancer.
  • Our study provides a strategy for the development of personalized treatment for gastric cancer patients and offers potential value in predicting chemosensitivity in tumors."